Phaseline

Companies › TRIANA Biomedicines

TRIANA Biomedicines: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TRI-611
ALK molecular glue degrader
ALKPhase 1ALK-positive NSCLCMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07491497TRI-611Phase 1ALK-positive NSCLCOncologyMay 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

ALK (1)

Companies with the same targets

Pfizer Roche IDEAYA Biosciences CStone Pharmaceuticals Ascentage Pharma Group Novartis Shenzhen TargetRx Nuvalent Shanghai Fosun Pharmaceutical Industrial Development Betta Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.